Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis

NCT01150565 Phase 1 COMPLETED

The purpose of this study is primarily to evaluate the safety and tolerability of two dose levels of an investigational drug-delivery system (LiRIS) in patients who have moderate to severe symptoms of interstitial cystitis.

Details

Lead sponsor	Allergan
Phase	Phase 1
Status	COMPLETED
Enrolment	18
Start date	2010-07
Completion	2011-09

Conditions

• Interstitial Cystitis

Interventions

• LiRIS low dose and LiRIS high dose

Primary outcomes

• Cystoscopic examination — Days 1 and 14

Countries

Canada